Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The recombinant plasmid pBHIV1 carrying the long terminal repeat (LTR) of the human immunodeficiency virus 1 (HIV-1), linked to the chloramphenicol acetyl transferase (CAT) gene, was introduced into human and rat fibroblasts. Stable transfectants resistant to geneticin expressed CAT activity from the HIV-1 LTR. It was found that the cytotoxic drug cis-diammine(1,1-cyclobutanedicarboxylato)platinum(II) (carboplatin) at concentrations from 1 x 10(-6) to 1 x 10(-4) M does not stimulate the expression of CAT from the HIV-1 LTR. These results differ from previous studies with the related drug cis-diamminedichloroplatinum(II) which showed stimulation of gene expression from the HIV-1 LTR and suggest that carboplatin could be used in the treatment of cancer patients with Acquired Immune Deficiency Syndrome.

Original publication

DOI

10.1016/0006-2952(92)90592-7

Type

Journal article

Journal

Biochem Pharmacol

Publication Date

04/02/1992

Volume

43

Pages

650 - 654

Keywords

Acquired Immunodeficiency Syndrome, Animals, Carboplatin, Cell Division, Chloramphenicol O-Acetyltransferase, Cisplatin, Fibroblasts, Gene Expression Regulation, Enzymologic, HIV Long Terminal Repeat, Humans, Rats, Transfection